Diagnosis and treatment of acute pulmonary embolism  by Widimský, Jiří
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/crvasa
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 90010-8650/$ - see fro
http://dx.doi.org/10
nTel.: þ420 60671
E-mail address: wReview ArticleDiagnosis and treatment of acute
pulmonary embolismJirˇı´ Widimsky´n
Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republica r t i c l e i n f o
Article history:
Received 27 August 2013
Accepted 10 October 2013
Available online 18 October 2013
Keywords:
Diagnosis of pulmonary embolism
Novel antithrombotics
Treatment of pulmonary embolism
Thrombolytic treatment of
pulmonary embolismnt matter & 2013 The Cze
.1016/j.crvasa.2013.10.001
2937.
idimsky@seznam.cza b s t r a c t
Novelties include the introduction of sPESI, a simpliﬁed index of pulmonary embolism severity,
and hs-cTnT as a new biomarker, already in use in clinical practice.
Another novelty is the term unstable pulmonary embolism characterized by either the
presence of cardiogenic shock or the need for ventilatory support.
The main new information is the evidence of a large US study of treatment of unstable
pulmonary embolism reporting a 67% reduction in overall mortality of unstable patients when
treated with thrombolytic treatment when compared with the anticoagulation in the same
unstable patients.
The reduction was obtained across all age groups as well as in comorbid patients.
Results of the above study clearly show that, in the absence of absolute contraindications, all
unstable APE patients, including the elderly and comorbid patients, should be treated with
thrombolysis.
By contrast, the comparison of thrombolytic and anticoagulation therapy in the treatment of
submassive pulmonary embolism in the PEITHO trial provided unconvincing results, perhaps
because of the low mortality rates of the whole group of 1004 patients.
Also reported are data from a US study of embolectomies. Caval ﬁlter insertion reduced the
mortality rates in all analyzed groups. Based on the facts, it is believed another appropriate
indication is that of temporary cavalﬁlter insertion inpatientswith severemassiveAPE, inwhom
recurrence of pulmonary embolism from pelvic veins has not been ruled out by CT venography.
Hemodynamically stable patients should be treated with LMWH or unfractionated heparins,
or rivaroxaban or apixaban.
At the end of hospitalization a control echocardiography and calculation of residual
pulmonary vascular obstruction on a perfusion scan should be performed.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights
reserved.
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The diagnosis of acute pulmonary embolism (APE) is a most
challenging issue. In most patients not examined with
imaging techniques, one can only guess the degree of prob-
ability at most.
Clinico-pathological studies suggest as little as 30–50% of
cases of ACE are correctly recognized [1].
The mortality rates of unrecognized and untreated APE are
30% whereas the average mortality of recognized and treated
APE is 8%.
Generally, the correctness of a diagnosis decreases
with patient’s age; it is lower in patients with co-existingbronchopneumonia while being increased in patients with
deep venous thrombosis.
In 85% of patients, APE develops secondary to deep venous
thrombosis involving not only the proximal but, also, popli-
teal veins; in other patients, sources of pulmonary embolism
include the pelvic and renal veins, vena cava inferior, and
right heart, and other.
As it is critical to even consider the possibility of APE, one
should not fail to consider the possible presence of APE in
patients with predisposing risk factors. Factors predisposing
to the development of venous thrombosis with subsequent
pulmonary embolism include the Virchow triad: changes in
coagulation, venous wall lesions, and decreased blood ﬂow rates.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 9 e4991.1. Risk factors for APE
Risk factors listed in the 2003 British Thoracic Society guide-
lines [2] are shown in Table 1.
Patient populations indicated for thrombophilic factor
testing are listed in Table 2.
About 50% of cases of pulmonary embolism/venous throm-
bosis occur in individuals without any identiﬁable clinical and
laboratory risk factors.2. Diagnosis
2.1. Clinical presentation and course
Table 3 compares APE classiﬁcations in the guidelines of the
Czech Society of Cardiology [3] and the European Society of
Cardiology (ESC) [4].
The main reason for the different European classiﬁcation
of APE is that radiologists interpreting CT angiograms (CTA)
often refer to pulmonary embolism as a massive one. As a
result, physicians may mistake massive pulmonary embo-
lism diagnosed clinically by hemodynamic instability for
CTA-documented “massive” pulmonary embolism in a hemo-
dynamically stable patient.
2.1.1. Acute massive pulmonary embolism (high-risk
pulmonary embolism)
Massive pulmonary embolism is a clinical entity characterized
by hemodynamic instability. It is associated with a grim prog-
nosis and the mortality of even treated massive pulmonary
embolism is in the range of 30–50%.
Acute massive pulmonary embolism may lead to sudden
death (occurring in approx. 10% of cases of massive pulmonary
embolism). Two out of three victims of massive pulmonary
embolism die within 2 h of the event.
Massive pulmonary embolism also result in the develop-
ment of cardiogenic shockwith hypotension, oliguria, confusion,
cold, sweating, and pale skin and, occasionally, cyanosis.
The diagnosis of massive pulmonary embolism should
also be established in patients requiring ventilatory support.
Additionally, massive pulmonary embolism may lead to
hypotension devoid of signs of shock. Hypotension is deﬁned as aTable 1 – Risk factors for venous thromboembolism according
Major risk factors (relative risk, 5–20%)
Post-operative states: major abdominal/pelvic surgery, hip/knee joint rep
malignancies, advanced/metastatic phase, status after documented prev
Table 2 – Reasons for indicating patients for thrombophilic fac
– Pulmonary embolism and/or venous thrombosis in those aged below 4
– Idiopathic pulmonary embolism and/or venous thrombosis
– Recurrent pulmonary embolism and/or venous thrombosis
– Venous thrombosis occurring in an unusual location
– Family history of pulmonary embolism and/or venous thrombosis
– Women with a history of pulmonary embolism during pregnancy andsystolic blood pressureo90 mmHg or a sudden drop in
systolic blood pressure by at least 40 mmHg and lasting
Z15 min, not caused by a sudden arrhythmia or hypovole-
mia. Tachycardia and tachypnea as such without hypoten-
sion do not suggest hemodynamic instability.
2.1.2. Acute submassive pulmonary embolism (intermediate-
risk pulmonary embolism)
While its clinical course is characterized by hemodynamic
stability, echocardiography will detect signs of right ventri-
cular dysfunction. The mortality of patients with signs of right
ventricular dysfunction is about twice that of stable
patients without right ventricular dysfunction [5]. The ESC
Guidelines [4] also underline the increased risk of patients with
right ventricular dysfunction associated with increased troponin
levels.
2.1.3. Acute minor pulmonary embolism (low-risk pulmonary
embolism)
A characteristic feature of this condition is the absence of
hypotension or shock as well as the absence of signs of right
ventricular dysfunction and myocardial injury [4]. Acute minor
pulmonary embolism will typically present with tachypnea
(24 breaths/min and more) and tachycardia. An even smaller-
extent pulmonary embolism may be silent or will only present
as a small increase in body temperature.
2.1.4. Incidence of individual clinical forms of APE:to
lac
iou
tor
5 y
plaAcute massive pulmonary embolism, 10–15%
Submassive pulmonary embolism, 35–40%
Minor pulmonary embolism, 50%The mortality of APE is higher than reported by smaller
studies to date. The ICOPER study [5] was actually an APE
registry including 2110 patients with diagnosis conﬁrmed by
autopsy or a lung scan.
The three-month APE mortality was 17.4%. After excluding
patients with pulmonary embolism not recognized until
autopsy, the three-month mortality decreased to 15.3%. The
ICOPER registry [5] showed that 5–10% of patients were in
cardiogenic shock upon admission to hospital with a mortal-
ity ranging between 25 and 50%.the 2003 British Thoracic Society guidelines [2].
ement surgery, lower limb fractures, abdominal/pelvic
s venous thromboembolism.
testing.
ears
nning another pregnancy
Table 3 – Classiﬁcations of APE in the guidelines of the Czech Society of Cardiology [3] and the
European Society of Cardiology [4].
CSC Guidelines [3] (the same classiﬁcation is used in the US) ESC Guidelines [4]
Massive pulmonary embolism High-risk pulmonary embolism
Submassive pulmonary embolism Intermediate-risk pulmonary embolism
Minor pulmonary embolism Low-risk pulmonary embolism
Table 4 – Revised Geneva score [6].
Parameters Points
Age over 65 years þ1
Previous venous thrombosis or pulmonary embolism þ3
Surgery or fracture within the last month þ2
Active malignancy þ2
Unilateral lower limb pain þ3
Hemoptysis þ2
Heart rate
75–94/min þ3
Z95 þ5
Lower limb pain on palpation and unilateral lower limb edema þ4
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 9e500The diagnosis of acute pulmonary embolism is based on:
Table 5 – Interpretation of the Geneva score.
0–3 Points Low probability– clinical probability determination;
4–10 Points Intermediate probability– D-dimer levels;
Z11 Points High probability– echocardiographic ﬁnding;– imaging techniques: CT angiography or ventilation-perfusion
scintigraphy.
2.1.5. Determination of clinical probability
This can be done using a simpliﬁed model of clinical prob-
ability of pulmonary embolism called the revised Geneva score
[6] and based exclusively on clinical parameters (Table 4).
Interpretation of the clinical probability according to the
Geneva Score is shown in Table 5.
Table 6 presents the Simpliﬁed Pulmonary Embolism
Severity Index (sPESI) [7].2.1.6. D-dimers
D-dimers are produced by the action of plasmin on ﬁbrin.
Based on their high negative predictive value, determination of
D-dimers is crucial for ruling out the diagnosis of pulmonary
embolism or venous thrombosis during outpatient assessment.
However, D-dimer positivity is associated with all conditions
synonymous with ﬁbrinemia such as inﬂammation, necrosis,
malignancy, infection, and so on, resulting in their low speci-
ﬁcity. Additionally, D-dimer speciﬁcity is decreased in the
elderly, pregnant women, those with malignancies, and in
hospitalized patients. Taken together, the diagnostic value of
increased D-dimer levels is limited.
D-dimer levels should be determined using ELISA or LIA
techniques. ELISA and LIA techniques are associated with
good sensitivity and mediocre speciﬁcity. The sensitivity of
whole-blood agglutination and latex tests is about 85% pre-
cluding their use to rule out the presence of pulmonaryembolism or venous thrombosis. The 2000 ESC guidelines
[8] consider these tests inappropriate!! The ﬁnding of nega-
tive D-dimers in patients with low or intermediate clinical
probability of venous thromboembolism excludes out the
presence of pulmonary embolism and venous thrombosis.
D-dimer levels are not determined in cases with high clinical
probability of pulmonary embolism.3. Cardiac biomarkers
3.1. Troponins
Increased cardiac troponin levels are present not only in
acute cardiac syndrome; they may also be found in APE.
In APE, elevated cardiac troponins help stratify hemodyna-
mically stable normotensive patients.
An increase in cTnT levels seems to be a discriminating factor
distinguishing patients with high and low mortality
While its negative predictive value is 0.99, the positive
predictive value is as low as 0.34.
The ﬁnding of increased cardiac troponins together with
right ventricular dysfunction identiﬁes the group of patients
at a substantially higher risk.
Troponin levels should be determined on admission and
again after an interval of 6–7 h as the levels do not peak
before 6–12 h after the development of APE.
A meta-analysis of 20 studies published since 1998 and
involving 1985 APE patients with determined troponin levels
Table 6 – The Simpliﬁed Pulmonary Embolism Severity Index.
Age480 years 1 Point
History of malignancy 1 Point
History of heart failure or lung disease 1 Point
Systolic blood pressureo100 mmHg 1 Point
Heart rate4110 beats/min 1 Point
SaO2o90% 1 Point
Low risk¼0 point; 1 and more points¼high risk.
The score is associated with a high negative predictive value of 99%.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 9 e501showed that any increase in troponins is associated with a
ﬁvefold increase in the risk of death [odds ratio, OR 5.24; 95%
CI 3.28–8.38] and an increased risk of death due to pulmonary
embolism (OR 9.44; 95% CI 4.14–21.49) [9].
A recent meta-analysis of 13 studies including only normo-
tensive patients (n¼1132) has demonstrated that increased
troponin levels are associated with an increased risk of early
death (OR 7.6) and increased risk of complicated hospitalization
(OR 6.8) [10].
Increased troponin levels per se do not necessarily imply a poor
prognosis [10]
Borderline values have not been deﬁned to date.
3.2. Natriuretic peptides: brain natriuretic peptide (BNP)
and N-terminal (NT)-proBNP
In APE patients, increased levels of BNP and NT-proBNP are
associated with right ventricular dysfunction. Elevated levels
of natriuretic peptides on admission signal an increased risk
of death from APE.
Natriuretic peptide levels are also increased in patients
with right ventricular pressure load due to causes other than
pulmonary embolism, including pulmonary arterial hyper-
tension, chronic thromboembolic pulmonary hypertension,
and pulmonary hypertension in the presence of lung or heart
disease. An increase in natriuretic peptides is a characteristic
feature of heart failure.
A recent meta-analysis of 13 studies involving a total of
1132 patients with pulmonary embolism increased BNP or
NT-pro BNP levels in 51% of subjects. The increase was
associated with an increased risk of early death (OR 7.6; 95%
CI 3.4–17) and complicated in-hospital course (OR 6.8; 95% CI
4.4–10) [11].
3.3. Novel biomarkersa) Heart-type fatty acid binding protein (H-FABP)
b) Growth differentiation factor-15 (GDF-15)
c) High-sensitivity troponin T (hs-cTnT)a) Heart-type fatty acid binding protein:
Heart-type fatty acid binding proteins (H-FABPs) are relatively
small cytoplasm molecules (12–15 kDa) that are found in
tissue with active metabolism of fatty acids including the
myocardium. In fact, H-FABPs are crucial for myocardial
homeostasis as 50–80% of cardiac energy comes from lipid
oxidation and H-FABP enables intracellular transport of
insoluble fatty acids. In myocardial injury, these smallproteins spread around the interstitial space much faster
than troponins and reach blood stream as early as 90 min after
the onset of symptoms,with their levels peaking within 6 hours.
Heart-type fatty acid binding proteins have been shown to
have an excellent negative prognostic value of 100% [12].
Their positive prognostic value is higher than that of
troponin T or NT-proBNP. The positive prognostic value is
further markedly increased by a combination of increased
H-FABP and right ventricular dysfunction. Elevated H-FABP
levels on admission serve as a strong predictor of a
complicated course of APE within the next 30 days [12].
Heart-type fatty acid binding protein cut-off levels have
been set as 6.0 ng/ml, with a sensitivity and speciﬁcity of
0.89 and 0.82, respectively. Patients with admission H-FABP
levels Z6.0 ng/ml had a 35.6 times higher risk of a compli-
cated 30-day course and 4.5 times higher risk of death
during long-term follow-up [12].b) Growth differentiation factor-15:
Growth differentiation factor-15 (GDF-15) is a cytokine
produced, in ischemia or pressure load, by macrophages
and other cell types as a response to a variety of stressors
including pro-inﬂammatory cytokines. Under normal con-
ditions, GDF-15 is not produced by the myocardium. Blood
levels of GDF-15 provide independent prognostic informa-
tion in patients with acute coronary syndrome or heart
failure. In 2008, Lankeit et al. [13] measured GDF-15 levels in
123 APE patients. These authors set the upper limit at
1200 ng/l. Patients with increased GDF-15 levels tended to
be older, were more often in cardiogenic shock or had
chronic heart failure, diabetes mellitus, a malignancy or
renal dysfunction. No patient with GDF-15 levels below
1200 ng/l experienced major complications within the ﬁrst
30 days. The prognostic value of GDF-15 was set by Lankeit
et al. [13] at 4600 ng/l, associated with a prognostic sensi-
tivity and speciﬁcity of 0.71 and 0.90, respectively, and a
negative prognostic value of 0.95. In the above study, GDF-
15 levels were raised not only by cardiogenic shock and
heart failure but, also, by extracardiac factors such as
malignancy, diabetes, and renal dysfunction. As a result,
the myocardial speciﬁcity of GDF-15 may be lower than
that of NT-proBNP and cardiac troponins. However, GDF-15
may be used with advantage when combined with right
ventricular dysfunction as this combination was prognos-
tically more accurate than right ventricular dysfunction in
combination with elevated troponin T or NT-proBNP.c) High-sensitivity troponin T:
Conventional troponins have a low prognostic sensitivity
and a negative prognostic value.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 9e502In the study by Lankeit et al. [14], high-sensitivity troponin
T (hs-cTnT) was determined using quantitative electro-
chemiluminescent immunoassay (Elecsyn 2010 analyzer,
Roche Diagnostics, Mannheim, Germany). The value of
hs-cTnT was compared with that of conventional cTnT in
156 normotensive patients developing APE [14]. Cut-off
levels of hs-cTnT were at 14 pg/ml. High-sensitivity TnT
levels Z14 pg/ml were compared with those of conven-
tional troponin TZ0.03 ng/ml and NT-proBNP Z1000 pg/
ml. Patients with a complicated course showed signiﬁ-
cantly higher hs-cTnT levels than those with an uncompli-
cated course; 71.7 (35.5–117.9) versus 26.4 (9.2–68.2) pg/ml;
p¼0.027. Patients with normal hs-cTnT levels (o14 pg/ml)
had a favorable prognosis. The authors thus demonstrated
that, in contrast to hs-cTnT, conventional troponins are
unable to differentiate between increased and normal risk
[14].
The negative prognostic value of hs-cTnT is 100% as is its
positive predictive value.
Unlike conventional cTnT and NT-proBNP, hs-cTnT has also
been shown to be a valuable prognostic tool in long-term
prognosis.
In a multicenter, multinational cohort of 526 normotensive
APE patients, hs-cTnT showed a high negative prognostic
value (98%) comparable with the negative predictive value of
sPESI (99%) [14].
Hence, right ventricular dysfunction, as assessed by echocar-
diography or CT angiography, when combined with elevated
hs-cTnT currently appears to be the most reliable tool for risk
stratiﬁcation in normotensive patients with APE [15].
The above novel biomarkers, particular hs-cTnT and
H-FABP, are characterized by positive and negative predictive
values superior to those of the currently used biomarkers
(troponins and NT-proBNP).4. Echocardiography
Echocardiography plays a pivotal role not only in determining
the risk of APE but, also, in distinguishing other acute cardiac
conditions.
Major APE is typically characterized by a combination
of right ventricular dilatation, free wall hypokinesis, and
increased end-diastolic right-to-left ventricular dimension
ratio. Other signs include abnormal septal motion (ﬂattening
up to its bulging toward the left ventricle), right atrial
dilatation, dilatation of the proximal segments of pulmonary
veins and dilatation of the vena cava inferior with its limited
collapse depending on respiration.
A concomitant ﬁnding of pulmonary hypertension (peak
tricuspid regurgitation ﬂow 11 velocity 42.5 m/s) and right
ventricular dilatation (right-to-left ventricular dimension
ratio 40.5) has a sensitivity as high as 93%, speciﬁcity of
81%, and a negative predictive value of 94% in the diagnosis
of pulmonary embolism.
Right ventricular dilatation is deﬁned as an end-diastolic
right ventricular size 430 mm measured from the paraster-
nal long-axis projection or an end-diastolic right-to-left
ventricular dimensions ratio 40.5.Right ventricular dysfunction develops in 30–40% of hemo-
dynamically stable APE patients and, also, in unstable APE
patients. In everyday practice, the ﬁnding of right ventricular
dilatation should alert the physician to the possibility of its
dysfunction.
However, it should be noted that a normal echocardiogram
will not completely rule out APE as up to 20% of APE patients
have a normal echocardiographic ﬁnding. Echocardiography is
most helpful particularly in distinguishing other causes of
hemodynamic instability, dyspnea, chest pain, or elevated bio-
marker levels. It will readily recognize left ventricular systolic
dysfunction in coronary heart disease or dilated cardiomyopa-
thy, myocarditis or valve disease resulting in the dyspnea or
pulmonary hypertension. Similarly, it will identify cardiac tam-
ponade or aortic dissection as the cause of arterial hypotension.
Even in hemodynamically stable patients, right ventricular
dysfunction is associated with a death rate as high as a
double that of patients without this condition [4].
Lamentably, there has not been consensus in the literature
regarding the deﬁnition of right ventricular dysfunction result-
ing in different rates of its incidence and prognostic value
reported by individual authors. This heterogeneity was under-
lined by the meta-analysis of echocardiographic studies by
Sanchez et al. [16]. Therefore, also the current guidelines for the
diagnosis and treatment of pulmonary embolism recommend
to use in clinical practice, for simplicity sake, mere signs of
right ventricular dilatation, as a manifestation of right ventri-
cular dysfunction. In their meta-analysis, Sanchez et al. [16]
also point to the relatively low overall speciﬁcity (57%) and
positive predictive value (58%) of echocardiography.
In hospitals, echocardiography should be available on a
24/7/52 basis.5. Imaging techniques
5.1. Spiral CT angiography (CTA)
Indirect CT venography (CTV) allows for scanning the pelvic
veins, vena cava inferior, and retroperitoneum except for
lower limb veins.
5.1.1. Diagnostic accuracy of CTA
In the case of central involvement up to the level of seg-
mental vessels, the diagnostic accuracy of CTA is in excess of
95%. The assessability of the peripheral vasculature depends
on the technical characteristics of the device employed.
Based on data from PIOPED II study, spiral CT angiography
performed using ﬁrst-generation (i.e., single-slice) devices has
been shown to have low sensitivity (as low as 70%) [17]. As the
sensitivity of lung scintigraphy is higher, it is recommended to
complement the assessment, in cases of a negative ﬁnding
with ﬁrst-generation CT angiograms, with the former technique.
Luckily enough, 4-slice devices have virtually the same accuracy
as conventional catheter pulmonary angiography.
Spiral CTA using a 4-, 16-, and 64-slice device allows for better
imaging of segmental and subsegmental arteries. The negative
predictive value of catheter-based pulmonary angiography (the
“gold standard”) is 96.4% according to van Beek et al. [18] and
100% according to Henry et al. [19] and is not superior to the
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 9 e503negative predictive value ofmultislice CTA being 99.1% according
to a meta-analysis performed by Quiroz et al. [20].
In addition, CTA makes it possible to detect the presence
of right ventricular dilatation [21]. In the CTA scan, right
ventricular dilatation is deﬁned as a right ventricular dia-
meter Z90% than the left ventricular diameter [21].
Right ventricular dilatation deﬁned as a right-to-left ven-
tricular dimension ratio 40.9 was associated with an OR for
sudden death of 5.2 (p¼0.03) and total 30-day mortality of
16% compared with an 8% death rate of patients without right
ventricular dilatation [21].5.1.2. Role of indirect CT venography
Results of the PIOPED II trial [18] using 4- to 16-detector CTA
showed that CTV can improve CTA sensitivity from 83% to
90%. However, it should be remembered that the combination
of CTA and CTV raises radiation exposure, a fact that should
be borne in mind especially in young patients.
Patients with high clinical probability of APE and with
negative CTA and CTV ﬁndings require additional examina-
tions, either repeat ultrasound or CT, or even MRI (to assess
their venous system), a ventilation-perfusion scan or catheter
lung angiography.
Spiral CTA also allows to examine the lungs and pleural
cavities thus detecting, e.g., a tumor, pleural effusion, atelec-
tasis, pneumothorax, lymphadenopathy, emphysema, lung
edema in heart failure, lung ﬁbrosis, as well as aortic dissec-
tion, and other pathologies.5.2. Lung scintigraphy
Lung perfusion scan is a highly sensitive yet not too speciﬁc
technique to detect pulmonary embolism. A negative lung
perfusion scan obtained in 4–6 projections on day 1 of onset
of symptoms will reliably rule out the diagnosis of APE. Given
its negative predictive value close to 100%, it is an ideal
screening technique.
The speciﬁcity of lung perfusion scintigraphy can be
enhanced by simultaneous ventilation or inhalation scan,
which will help explain the absence of perfusion for reasons
other than pulmonary embolism. A ventilation scan allows to
assess the distribution of inhaled radioactive xenon-133
or crypton-81 m or labeled radioaerosol in the lungs. This
is because the absence of perfusion may also be due to
pulmonary bulla, atelectasis, pneumonia, chronic obstructive
lung disease (COLD), and other lung conditions as well as left-
heart failure. In bullous emphysema, atelectasis and in COLD,
a ventilation scan is abnormal (bulla-related hypoventilation)
while it is normal in pulmonary embolism.
The speciﬁcity of lung SPECT scintigraphy is increased to a
range of 91–96%; its negative predictive value is somewhere
between 97% and 99% [22].
The speciﬁcity of a lung perfusion scan is appreciably
enhanced by a lobar or segmental shape of the perfusion
defect and a negative ventilation scan.
By contrast, one or several perfusion defects of non-wedged
shape with or without concomitant chest x-ray abnormalities is
not indicative of pulmonary embolism as deﬁned by PISA-PED
study [23].However, lung scintigraphy is not devoid of several draw-
backs, one of them being inconclusive ﬁndings. The most
valuable ﬁnding is a negative one or a ﬁnding associated high
probability of APE, i.e., the presence of one or several wedge-
shaped segmental defects irrespective of whether they are or
are not suggestive of a co-existing lung pathology.
Another disadvantage of lung scintigraphy is that, except
for several centers, the technique is not available on a 24/7/52
basis; as a result, it is more often employed to additionally
conﬁrm the diagnosis, clearly not an optimal solution.
While CTA has clearly become the ultimate technique in
the diagnosis of APE, lung scintigraphy has retained its role in
the following situations, as shown in Table 7.6. Treatment
6.1. Initial treatment
Normal unfractionated heparin (UFH) (5000–10,000 U) should
be given to all patients with high or intermediate probability
of APE without waiting for results of imaging techniques.
Critically ill patients may occasionally require emergency
veno-arterial extracorporeal membrane oxygenation (C-A
EMCO) [24].
6.2. Thrombolytic therapy
Indications for thrombolytic therapy are listed in Table 8.
Alarming data were recently reported by Stein and Matta
[25]. The authors analyzed data of APE patients treated in US
hospitals between 1999 and 2008. The authors found that as
little as 30% of unstable patients with APE are treated with
thrombolysis.
Unstable APE was characterized either by the presence of
cardiogenic shock or the need for ventilatory support.
The thrombolytic therapy in unstable pulmonary embolism
patients was associated with a decrease of 67% in mortality
when compared with anticoagulation treatment in unstable
patients.
The incidence of intracranial hemorrhage was low being
only 0.9%.
The probability of thrombolysis initiation was lowest in
elderly patients and those with one or several comorbidities.
Still, the mortality of thrombolysis-treated patients was
consistently lower compared with that of patients treated
with anticoagulation whatever the age group.
To illustrate the above, the mortality of unstable patients
r60 years was 16%, but that of anticoagulation-treated patients
was 39%.
In the 80þ age group, mortality of thrombolysis- and
anticoagulation-treated patients was 25% and 57%, respectively.
In unstable patients with one or several comorbidities
(across all age groups), the mortality rates associated with
thrombolysis and anticoagulation therapy were 8% vs. 41%.
Dalen [26] suggested that the results reported by Stein and
Matta clearly show that, all unstable patients with APE in the
absence of absolute contraindications should be treated with
thrombolysis, including the elderly ones and individuals with
comorbidities.
Table 7 – Indications for lung scintigraphy.
– In centers where spiral CT is unavailable
– In centers where only single-slice spiral CT is available
– In patients with a negative multislice CTA, yet high clinical probability of the diagnosis
– In patients with renal failure (glomerular ﬁltration rateo30 ml/min)
– In patients with allergy to contrast media
– In women with a child-bearing potential (lower radiation exposure to the breast)
Table 8 – Indications for thrombolytic therapy in acute pulmonary embolism.
– Massive pulmonary embolism including pulmonary embolism requiring ventilatory support
– Pulmonary embolism not responding to heparin therapy
– Recurrent and increasing pulmonary embolism
– A patent foramen ovale with right-left shunt
– Right-heart thrombus
A questionable indication is submassive pulmonary embolism, i.e., stable APE but with right ventricular dilatationþincreased hs-cTnT.
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with elevated troponin levels and right ventricular dysfunction
should be treated with thrombolysis. According to the ESC
guidelines, thrombolysis should be considered in stable nor-
motensive patients with signs of right ventricular dysfunction
but no suspected increased risk of bleeding complications.
A large multicenter European trial (PEITHO) designed to
compare thrombolysis with anticoagulation treatment in
patients with submassive pulmonary embolism deﬁned as
right ventricular dysfunction and elevated hs-cTnT. Tenecte-
plaseþheparin were compared with heparinþplacebo. While
a signiﬁcant decrease in the primary endpoint (deathþhemo-
dynamic collapse) was found with tenecteplase (2.6% vs.
5.9%; p¼0.015), major bleeding was signiﬁcantly more frequent
in the tenecteplase-treated group (6.3% vs. 1.5%). The overall
results were thus not convincing
Striking ﬁndings included the higher incidence of bleeding
complications and the relatively low mortality of the whole
group.
However, the PEITHO trial has not been published and
only presented at the Annual Meeting of the ACCy held in San
Francisco in 2013.
Bělohlávek et al. [24] correctly point to the fact the risk of APE
patients is signiﬁcantly increased by respiratory failure, renal
failure, higher age, and pre-existing heart disease. Therefore, the
authors use the term serious pulmonary embolism including, e.
g., patients with a right-heart mobile thrombus or those with
patent foramen ovale.
Unlike acute myocardial infarction, thrombolysis can also be
initiated later, i.e., as late as 2 weeks since the onset of initial
symptoms, e.g., in patients unresponsive to heparin therapy or
in the presence of progressive or persistence of a critical status.7. Overview of thrombolytics
7.1. Alteplase should be the thrombolytic drug of choice
Alteplase, a tissue plasminogen activator (t-PA), is adminis-
tered at a dose of 10 mg i.v. in bolus form within 1–2 min,
followed by 90 mg t-PA as continuous i.v. infusion for 2 h.In patients with a relative contraindication to thrombolytic
therapy, it is advisable to administer alteplase at a dose of
0.6 mg in bolus form over a period of 15min.
7.2. Streptokinase
With streptokinase, short-term treatment of pulmonary embo-
lism should preferably use a dose of 1.5 mil U infused over 1–2 h.
Streptokinase should not be administered to patients treated
with this agent before. Unlike alteplase, streptokinase should
not be combined with heparin infusion. Shorter streptokinase
infusion does not require evaluation of hemocoagulation
parameters.
7.3. Tenecteplase
The main advantage of tenecteplase is that it can be admi-
nistered as a single-bolus (30–50 mg) over 5–10 s. The dose
depends on the patient's body weight. The product has not
been approved for use in the Czech Republic.
The beneﬁcial effect of thrombolytics is greatest if admi-
nistered within 48 h of onset of symptoms; however, these
agents can also be used in patients with persistent symptoms
or deteriorating state lasting 6–14 days.
7.4. Contraindications to thrombolytic therapy as deﬁned
by the 2008 ESC guidelines [4]
Absolute contraindications:– A history of a hemorrhagic stroke or undetermined stroke
– Ischemic stroke within the last 6 months
– Central nervous system neoplasm
– Major trauma, surgery, or head injury within the last 3 weeks
Relative contraindications:– TIA within the last 6 months
– Oral anticoagulation therapy
– Pregnancy or the ﬁrst week post-delivery
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– Traumatic resuscitation
– Resistant hypertension (systolic BP4180 mmHg)
– Advanced liver disease
– Infective endocarditis
– Active ulcerative diseaseEuropean guidelines [4] make it possible to relativize even
absolute contraindications of thrombolytic therapy of APE in
cases of life-threatening pulmonary embolism.7.4.1. Side effects of thrombolytic therapy
The most frequent side effects of thrombolytic therapy,
irrespective of the agent, are bleeding complications. Most
often, bleeding is due to an occult mucosal defect or dis-
regarded contraindication. While cerebral hemorrhage will
occur in 1–2% of patients, heparin therapy will also result in
cerebral hemorrhage in 0.5% of individuals. As the risk of
bleeding complications increases with thrombolytic therapy
duration, only short-term thrombolytic therapy protocols
lasting 2 h at most are used. Thrombolysis-related bleeding
is managed by hemotherapy, i.e., infusion of a red blood cell
concentrate or plasma.8. Pulmonary embolectomy
Pulmonary embolectomy should be considered in emergen-
cies; these include the critically ill, patients with deteriorating
health status during thrombolysis, and individuals with
contraindications to thrombolytic therapy due to high risk
of bleeding. As a rule, a temporary caval ﬁlter is inserted
during embolectomy. A group of controversial indications
includes patients developing out-of-hospital heart arrest with
failed attempts to resume cardiac action preoperatively,
those with an inoperable malignant tumor or a major neuro-
logical deﬁcit. In some centers, patients above 80 years of age
are not considered suitable candidates for embolectomy if
presenting with some relative contraindications (e.g., failed
thrombolytic therapy).
Stein and Matta [27] reported the mortality rates of pul-
monary embolectomy in the US. In unstable patients, mortality
related to pulmonary embolectomy combined with caval ﬁlter
insertion was 25% (n¼520); the rate was substantially higher,
58% (n¼430), in unstable patients without caval ﬁlter insertion.
The authors also reported the mortality related to pulmonary
embolectomy in stable patients with and without caval ﬁlter
insertion, being 14% (n¼1508) and 36% (n¼1.320), respectively.
Embolectomy can be considered in stable patients developing
new-onset hemodynamic instability, worsening of respiratory
failure, severe right ventricular dysfunction, or major myocar-
dial necrosis [28]. Even so, the rates of pulmonary embolect-
omy performed in stable patients strikingly outnumber the
ﬁgures reported for unstable patients [26].
In summary, those with optimal indication for embolect-
omy include patients with massive pulmonary embolism
contraindicated for thrombolytic therapy and individuals
with failed thrombolytic therapy.9. Catheter-based treatment of APE
This option is indicated in patients (a) with thrombolytic
therapy contraindication; (b) with failed thrombolytic therapy
and, (c) with contraindicated or unavailable surgical embo-
lectomy [29,30].
Catheter-based therapy makes use of (1) thrombus frag-
mentation with a standard pig-tail catheter; (2) rheolytic
thrombectomy (Angiojet device); (3) aspiration thrombect-
omy; (4) rotational thrombectomy (Aspirex catheter).
A currently promising technique seems to be percutaneous
mechanical thrombectomy (PMT) of the blood clot using a
catheter with or without subsequent thrombolysis, allowing for
rapid recanalization of central pulmonary arteries; however, this
technique has not been evaluated in a single randomized trial
to date.
A meta-analysis of treatment of massive pulmonary
embolism (6 prospective and 29 retrospective studies) using
latest catheter-based techniques and technology (low-proﬁle
devicesr10 F, fragmentation devices with and without
aspiration, local thrombolysis) has documented a clinical
success rate of 86.5% in 594 patients [31]. Major complications
were reported in 2.1% of patients [31].
Catheter-based therapy should only be considered in centers
with ample experience with this type of therapy.10. Caval ﬁlter
Treatment with a caval ﬁlter is indicated in the following cases:– In patients with anticoagulation therapy either contra-
indicated or associated with a risk (malignancy, acute
bleeding during anticoagulation therapy, postoperative
status, especially after neurosurgery).– In patients developing documented recurrent pulmonary
embolism while receiving appropriate anticoagulation
therapy.– In patients with severe massive APE in whom CT veno-
graphy has not ruled out pulmonary embolism from pelvic
veins.– In at-risk patients scheduled for surgery in whom prophy-
lactic caval ﬁlter insertion is appropriate (temporary caval
ﬁlters are available).– In patients indicated for suprarenal caval ﬁlter placement,
particularly in those with the thrombus extending to
the site where renal veins enter the kidneys, and in
women either pregnant or those planning to become
pregnant.The study by Stein et al. [32] has clearly shown that caval
ﬁlter insertion will reduce mortality in unstable patients,
not only those treated with thrombolysis but, also, in those
treated only with anticoagulation therapy.
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In stable patients, APE is with treated with i.v. heparin, low-
molecular weight heparin or fondaparinux [33].
The efﬁcacy of treatment with unfractionated heparin
(UFH) is assessed using activated partial thromboplastin time
(aPTT). At effective UFH doses, aPTT should become two to
four times longer compared with normal values.
Treatment with UFH is initiated with a bolus of 5000–
10,000 IU, given to all patients with high or intermediate
probability of APE as soon as possible, even before this
conﬁrmed by imaging techniques [33,34].
Treatment with i.v. heparin andwarfarin should be continued
for at least 72 h [and should be withdrawn when reaching an
international normalization ratio (INR) of 2–3 with concomitant
warfarin therapy on two consecutive measurements.]
The recommended duration of i.v. anticoagulation therapy
of pulmonary embolism using UFH is not shorter than 5 days,
usually 6–10 days.
Indications for the use of i.v. UFH are listed below:– Patients with severe kidney injury (creatinine clearance
o20–30 ml/min)– Patients at high risk of bleeding
– Individuals (usually) with extreme overweight and under-
weight– Elderly patients
All other patient groups should be given LMWH or
fondaparinux.
All heparin-treated patients should be monitored for
thrombocyte levels before and during therapy. A decrease in
thrombocyte levels below 100109 /l or a decrease by more
than a third may suggest immunopathological, heparin-
induced thrombocytopenia (HIT). Heparin-induced thrombo-
cytopenia, while more frequent after UFH (5%) than after
LMWH (0.5%) in orthopedic patients, occurs equally in
patients with medical conditions (UFH and LMWH, 0.8%).
Heparin-induced thrombocytopenia has been reported in up
to 6% of pregnant women receiving therapeutic doses of
LMWH; however, the risk is very low at prophylactic doses.
As heparin does not cross the placental barrier, it can be
administered in pregnancy (but not to pregnant women at risk of
bleeding). Likewise, heparin has not been detected in breast milk.
In orthopedic and abdominal surgical patients with massive
pulmonary embolism, the potential of bleeding risk should be
considered as should be the risk of failure to administer heparin.
11.1. Treatment with low-molecular weight heparin
Treatment of APE with LMWH in hemodynamically stable
patients is as effective as that with standard heparin. The
advantage of LMWH is that is LMWH therapy does not require
monitoring of laboratory parameters as a rule. Optimal
LMWH dosage depends on the patient's body weight.
Overview and dosing of low-molecular weight heparins:
Dalteparin 120 antifactor-Xa U/kg twice a day
Enoxaparin 100 antifactor-Xa U/kg twice a dayNadroparin 400 antifactor-Xa U/kg divided into two injec-
tion applications twice a day
Reviparin 6300 antifactor-Xa U/kg twice a day or 4200 U
twice a day in patients with a body weight of 46–60 kg
Tinzaparin 175 antifactor-Xa U/kg once a day
11.2. Warfarin
Treatment with warfarin is initiated together with initial
therapy with UFH or LMWH at a dose of 5–10 mg in an effort
to reach a target INR values of 2–3 within 5–6 days.
Long-term warfarin therapy is plagued with a variety of
drawbacks including the need for INR self-monitoring. Other
disadvantages include warfarin interaction with a host of
drugs and food resulting as it does in INR variability in many
patients. Self-monitoring of INR is convenient for the patient
as they do not have to present to the attending physician.
A meta-analysis of 11 studies involving 6417 patients
showed that INR self-monitoring, while helping reduce
the incidence of recurrent thromboembolic episodes by 50%,
does not decrease the incidence of bleeding complications
[35].
Rapid pharmacogenetic testing may improve the accuracy
of warfarin dosing [36,37]. More than a third of variability of
the effect of warfarin may be due to the action of two genes.
One of these genes determines the activity of CYP2C9, a liver
enzyme metabolizing the 5-enantiomer of warfarin to its
inactive form. The other gene affects the activity of vitamin
K epoxide reductase complex (VKORC1), an enzyme producing
the active form of vitamin K. Several studies are currently
ongoing in Europe, USA and Asia to document the beneﬁts
pharmacogenetic testing [38].
11.3. Novel antithrombotics
Novel antihrombotics are listed in Table 9.
Novel antithrombotics have their advantages and disad-
vantages. While undeniable advantages include the fact there
is no need for INR monitoring, disadvantages include their
shorter-term effect making them suitable for compliant
patients. Missing a single dose may result in a larger side
effect on thrombogenecity than missing a single dose of
warfarin. At the moment, there is no antidote despite rapidly
advancing research is in this ﬁeld [39]. Administration of
novel antithrombotics is not advisable in patients with
moderate renal insufﬁciency; they are also more costly than
warfarin. Warfarin remains to be the drug of choice in
artiﬁcial heart valve recipients. Novel antithrombotics are
suitable for patients with considerable variations in INR
values and, quite understandably, for those in whom INR
self-monitoring is immediately unavailable.
11.3.1. Dabigatran
Dabigatran at a dose of 150 mg twice a day was compared
with warfarin after initial therapy with LMWH for 6 months
in either group in the RE-COVER trial [40]. Recurrence was
observed in 2.4% vs. 2.1%; po0.001 (non-inferiority). While
bleeding events were more frequent in the warfarin group
21.9% vs. 16.1% (hazard ratio 0.71), major bleeding occurred
Table 9 – Novel antithrombotics.
Direct thrombin inhibitor: dabigatran administration after initial therapy with LMWH
Direct factor Xa inhibitors: rivaroxaban, apixaban administration since therapy initiation
Edoxaban administration after initial therapy with LMWH
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as effective as warfarin in the treatment of APE/venous
thrombosis.
11.3.1.1. Measures to be taken in the event of overdose or
bleeding
No speciﬁc antidote for dabigatran is currently available. Should
bleeding complications occur, therapy should be discontinued
and the source of bleeding identiﬁed. As dabigatran is eliminated
primarily via the kidney, it is critical to maintain adequate
diuresis. In patients experiencing severe and life-threatening
bleeding, it is recommended to consider blood transfusion, use
of charcoal (within 2 h of dabigatran administration), or a
prothrombin complex concentrate. As dabigatran is dialyzable,
charcoal hemodialysis or hemoﬁltration can be undertaken.
11.3.2. Rivaroxaban
The EINSTEIN-PE trial [41] compared treatment with rivarox-
aban or LMWH enoxaparin followed by warfarin. Recurrence
of symptomatic pulmonary embolism/venous thrombosis
was noted in 2.1% of the rivaroxaban-treated group and
3.0% in the group given enoxaparin/warfarin (n.s.). The
incidence of severe bleeding was lower in the rivaroxaban-
treated group (1.1% vs. 2.2%; p¼0.0032).
11.3.3. Apixaban
Whilst apixaban has shown promise in the prevention of
pulmonary embolism/venous thrombosis. The AMPLIFY
study has been ﬁnished [42] recently. It was a randomized,
double-blind study comparing apixaban (at a dose of 10 mg
twice daily for the ﬁrst 7 days, followed by 5 mg twice daily
for 6 months) with conventional therapy (subcutaneous
enoxaparin followed by warfarin) in 5395 patients with acute
venous thromboembolism. A ﬁxed dose of apixaban alone
was noninferior to conventional therapy in the treatment of
acute venous thromboembolism but was associated with
signiﬁcantly less bleeding.
11.3.4. Edoxaban
Edoxaban holds promise in the subgroup of APE patients with
decreased RV function, where it also signiﬁcantly reduces PE
recurrence rates compared with warfarin. It has not been
used in the Czech Republic so far.
No speciﬁc antidotes for rivaroxaban, apixaban, and edox-
aban are currently available.
11.3.5. Anticoagulation treatment duration– Patients with their ﬁrst-ever episode of pulmonary embo-
lism caused by a temporary risk factor should receive
therapy for at least 3 months.– In patients with idiopathic pulmonary embolism, treat-
ment should be continued for a minimum of 6–12 months.
In these patients, lifelong therapy should also be consid-
ered. In patients with idiopathic pulmonary embolism, the
risk of recurrent thromboembolism remains signiﬁcant
even after completion of 12-month therapy, with 30%
of patients experiencing pulmonary embolism/venous
thrombosis recurrence within the next 6 years.– Patients with a malignancy should receive LWMH over the
ﬁrst 3–6 months of long-term therapy either to be followed
by warfarin or until regression of the malignancy.– In patients with their ﬁrst-ever episode of pulmonary
embolism, and with antithrombin, protein C or S deﬁ-
ciency, or, hyperhomocysteinemia, or high levels of factor
VIII levels (490th percentile), therapy should be continued
for 6–12 months. Lifelong therapy as in idiopathic pul-
monary embolism should be considered.– In patients experiencing two or more episodes of docu-
mented pulmonary embolism a life-long anticoagulation
treatment should be considered.– In patients with their ﬁrst-ever episode of pulmonary
embolism, who have antiphospholipid antibody (antipho-
spholipid syndrome) or who have two or more thrombophi-
lic factors (e.g., combination of Leiden factorþprothrombin
G20,210A gene mutation), therapy should be continued for
12 months. Lifelong anticoagulation therapy should be
considered in these patients.
The randomized AMPLIFY-EXT trial [43] was designed to
compare two doses of apixaban (2.5 mg and 5mg) twice a day
versus placebo in patients with idiopathic thromboembolism
who had completed 6- to 12-month anticoagulation therapy to
determine whether or not their therapy should be continued.
The 12-month trial included a total of 2482 patients. Sympto-
matic recurrent venous thromboembolism was observed in
8.8% (73 of 829) of placebo-treated patients as against 1.7%
(14 of 840) patients receiving apixaban at a dose of 2.5 mg and
1.7% (14 of 813) of patients treated with 5 mg apixaban. The
difference was 7.0% (po0.001). Major bleeding rates were 2.3%
of the placebo group, 3.0% in the 2.5 mg apixaban-, and 4.2% in
the 5 mg apixaban-treated groups.
Continued anticoagulation prevention reduced the risk of
recurrent venous thromboembolism without raising the risk
of bleeding complications.
The efﬁcacy and safety of dabigatran at a dose of 150 mg
twice a day as compared with warfarin and placebo was
evaluated in two trials (RE-MEDY and RE-SONATE) [44]. The
trials started with at least 3-month anticoagulation therapy.
Dabigatran was shown to be effective in extending treatment
of venous thromboembolism and was associated with a lower
risk of major or clinically signiﬁcant bleeding complications
than warfarin.
The ASPIRE trial [45] also documented the efﬁcacy of
aspirin at a dose of 100 mg at, in idiopathic pulmonary
Table 10 – Long-term follow-up of selected patient subgroups after acute pulmonary embolism.
– Patients with acute massive pulmonary embolism
– Patients with acute pulmonary embolism and systolic pulmonary artery pressure in the acute phase460 mmHg
– Patients with submassive pulmonary embolism
– Patients with idiopathic pulmonary embolism
– Patients with recurrent pulmonary embolism
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 9 7 – e 5 0 9e508embolism after 12-month anticoagulation therapy;
in the randomized ASPIRE and WARSAW trials, aspirin
reduced the incidence of recurrent venous thromboembolism
by a third. While, needless to say, aspirin is less effective
than anticoagulation therapy, it can be preferred in patients
at mild or moderate risk of recurrence. In patients at
high risk, preference should be given to anticoagulation
therapy.12. Statin treatment and the risk of recurrent
pulmonary embolism
Recent observation from a Dutch population-based registry
performed in period 1998–2008 has found that in patients
after an idiopathic PE statin treatment decreases the risk of
recurrent PE, irrespective of the presence or absence of
anticoagulation treatment [46]. Treatment with statins could
be an attractive alternative for anticoagulation treatment in
the long-term treatment of PE, if conﬁrmed by randomized
placebo-controlled trial.13. Long-term follow-up of selected patients
Long-term follow-up of the following patient subgroups is
advisable (Table 10).
Residual pulmonary vascular obstruction (RPVO) evalu-
ated by perfusion lung scans within 6-8 days after the onset
of treatment in patients with submassive (intemediate risk)
and massive (high risk) pulmonary embolism is a powerful
prognostic factor for a 6-month outcome. RPVO Z35% is
associated with increased risk of adverse events (death,
recurrrent PE and heart failure) at 6 months [47].
At the end of hospitalization echocardiography and perfusion
lung scan should be performed. Emphasis should be placed on
disappearance of signs of right ventricular dilatation and signs of
pulmonary hypertension and amount of RPVO. Patients with
signs of right ventricular dilatation or pulmonary hypertension
and/or those with RPVO Z35% should be controlled after 6
months.
Should the clinical ﬁnding deteriorate (exacerbation of
dyspnea) and signs of right ventricular dilatation and/or
pulmonary hypertension worsen or persist, or RPVO remains
unimproved, continuation of anticoagulation treatment is
necessary as well as a further control after further 3 months.
Some patients may develop chronic thromboembolic pul-
monary hypertension.r e f e r e n c e s
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